|
|
|
| Pathogenesis, clinical diagnosis and treatment of anorectal malignant melanoma: a review |
| ZHANG Yan1, NI Jing1, JIA Wengping1, XU Li2
|
1. The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China;
2. The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China |
|
|
|
|
Abstract Anorectal malignant melanoma (ARMM) is a subtype of malignant melanoma with low incidence and high invasion, and has a poor prognosis due to its hidden location and rapid progression. In terms of pathogenesis, the molecular landscape and potential carcinogenic driver gene characteristics of ARMM are significantly different from those of cutaneous melanoma, manifested by a lower rate of somatic mutations, no ultraviolet exposure-related mutation characteristics, a high incidence of cell structural variation, and high genomic instability. The tumor-driving genomic mutations are mainly KIT, NRAS, and NF1 mutations, and the incidence of SF3B1 mutations is significantly higher than that in other sites of mucosal melanoma. Surgery is still the main treatment for ARMM, while immunotherapy and targeted therapy need further development. This article reviews the characteristics of carcinogenic driver gene mutations and clinical diagnosis and treatment of ARMM, providing a reference for the prevention and treatment of ARMM.
|
|
Received: 01 September 2023
Revised: 26 October 2023
Published: 15 December 2023
|
|
|
|
|
|
[1] HEPPT M V,ROESCH A,WEIDE B,et al.Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma[J].Eur J Cancer,2017,81:36-44.
[2] SARAC E,AMARAL T,KEIM U,et al.Prognostic factors in 161 patients with mucosal melanoma:a study of German central malignant melanoma registry[J].J Eur Acad Dermatol Venereol,2020,34(9):2021-2025.
[3] SHAH N J,ALOYSIUS M M,BHANAT E,et al.Epidemiology and outcomes of gastrointestinal mucosal melanomas:a national database analysis[J/OL].BMC Gastroenterol,2022,22(1)[2023-10-26].https://doi.org/10.1186/s12876-022-02254-5.
[4] XIAO L,LUO Q Q,YUAN W J,et al.Effect of surgical treatment for anorectal melanoma:a propensity score-matched analysis of the Surveillance,Epidemiology,and End Results programme data[J/OL].BMJ Open,2022,12(4)[2023-10-26].https://doi.org/10.1136/bmjopen-2021-053339.
[5] D'MELLO S A,FINLAY G J,BAGULEY B C,et al.Signaling pathways in melanogenesis[J].Int J Mol Sci,2016,17(7):1-18.
[6] ELDER D E,BASTIAN B C,CREE I A,et al.The 2018 World Health Organization classification of cutaneous,mucosal,and uveal melanoma:detailed analysis of 9 distinct subtypes defined by their evolutionary pathway[J].Arch Pathol Lab Med,2020,144(4):500-522.
[7] MALAGUARNERA G,MADEDDU R,CATANIA V E,et al.Anorectal mucosal melanoma[J].Oncotarget,2018,9(9):8785-8800.
[8] JITIAN MIHULECEA C R,ROTARU M.Review:the key factors to melanomagenesis[J/OL].Life(Basel),2023,13(1)[2023-10-26].https://doi.org/10.3390/life13010181.
[9] JACKETT L A,SCOLYER R A.A review of key biological and molecular events underpinning transformation of melanocytes to primary and metastatic melanoma[J].Cancers(Basel),2019,11(12):1-21.
[10] NEWELL F,KONG Y,WILMOTT J S,et al.Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets[J].Nat Commun,2019,10(1):1-15.
[11] TEIXIDO C,CASTILLO P,MARTINEZ-VILA C,et al.Molecular markers and targets in melanoma[J].Cells,2021,10(9):1-31.
[12] GUO Y J,PAN W W,LIU S B,et al.ERK/MAPK signalling pathway and tumorigenesis[J].Exp Ther Med,2020,19(3):1997-2007.
[13] PALMIERI G,COLOMBINO M,CASULA M,et al.Molecular pathways in melanomagenesis:what we learned from next-generation sequencing approaches[J].Curr Oncol Rep,2018,20(11):1-16.
[14] PENG Y,WANG Y Y,ZHOU C,et al.PI3K/Akt/mTOR pathway and its role in cancer therapeutics:are we making headway?[J].Front Oncol,2022,12:1-17.
[15] STRASHILOV S,YORDANOV A.Aetiology and pathogenesis of cutaneous melanoma:current concepts and advances[J].Int J Mol Sci,2021,22(12):1-14.
[16] GARGALIONIS A N,PAPAVASSILIOU K A,BASDRA E K,et al.mTOR signaling components in tumor mechanobiology[J].Int J Mol Sci,2022,23(3):1-16.
[17] NASSAR K W,TAN A C.The mutational landscape of mucosal melanoma[J].Semin Cancer Biol,2020,61:139-148.
[18] LI H,YANG L J,LAI Y M,et al.Genetic alteration of Chinese patients with rectal mucosal melanoma[J].BMC Cancer,2021,21(1):1-9.
[19] DU M Z,WANG Y H,GU D M,et al.Identification of vital genes and pathways associated with mucosal melanoma in Chinese[J/OL].Ann Diagn Pathol,2021,50[2023-10-26].https://doi.org/10.1016/j.anndiagpath.2020.151648.
[20] PHAM D D M,GUHAN S,TSAO H.KIT and melanoma:biological insights and clinical implications[J].Yonsei Med J,2020,61(7):562-571.
[21] NAGARAJAN P,PIAO J,NING J,et al.Prognostic model for patient survival in primary anorectal mucosal melanoma:stage at presentation determines relevance of histopathologic features[J].Mod Pathol,2020,33(3):496-513.
[22] TERRELL E M,MORRISON D K.Ras-mediated activation of the raf family kinases[J].Cold Spring Harb Perspect Med,2019,9(1):1-14.
[23] INDINI A,ROILA F,GROSSI F,et al.Molecular profiling and novel therapeutic strategies for mucosal melanoma:a comprehensive review[J].Int J Mol Sci,2021,23(1):1-14.
[24] WRÓBLEWSKA J P,DIAS-SANTAGATA D,USTASZEWSKI A,et al.Prognostic roles of BRAF,KIT,NRAS,IGF2R and SF3B1 mutations in mucosal melanomas[J].Cells,2021,10(9):1-13.
[25] DUMAZ N,JOUENNE F,DELYON J,et al.Atypical BRAF and NRAS mutations in mucosal melanoma[J].Cancers(Basel),2019,11(8):1-13.
[26] TAO J Y,SUN D T,DONG L N,et al.Advancement in research and therapy of NF1 mutant malignant tumors[J].Cancer Cell Int,2020,20:1-8.
[27] HINTZSCHE J D,GORDEN N T,AMATO C M,et al.Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma[J].Melanoma Res,2017,27(3):189-199.
[28] HLUCHÝ M,GAJDUŠKOVÁ P,RUIZ DE LOS MOZOS I,et al.CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1[J].Nature,2022,609(7928):829-834.
[29] BLEICHER J,COHAN J N,HUANG L C,et al.Trends in the management of anorectal melanoma:a multi-institutional retrospective study and review of the world literature[J].World J Gastroenterol,2021,27(3):267-280.
[30] KOTTAKOTA V,WARIKOO V,YADAV AK,et al.Clinical and oncological outcomes of surgery in anorectal melanoma in Asian population:a 15 year analysis at a tertiary cancer institute[J/OL].Cancer Treat Res Commun,2021[2023-10-26].https://doi.org/10.1016/j.ctarc.2021.100415.
[31] NAFEES R,KHAN H,AHMED S,et al.Primary rectal amelanotic malignant melanoma:a rare case report[J].Cureus,2020,12(5):1-4.
[32] PARK H J,KIM H J,PARK S H,et al.Journal club:primary anorectal melanoma:MRI findings and clinicopathologic correlations[J].Am J Roentgenol,2018,211(2):98-108.
[33] 赖玉梅,李忠武,李欢,等.68例肛管直肠黏膜黑色素瘤临床病理特征及预后[J].北京大学学报(医学版),2023,55(2):262-269.
[34] TARIQ M U,UD DIN N,UD DIN N F,et al.Malignant melanoma of anorectal region:a clinicopathologic study of 61 cases[J].Ann Diagn Pathol,2014,18(5):275-281.
[35] JUTTEN E,KRUIJFF S,FRANCKEN A B,et al.Surgical treatment of anorectal melanoma:a systematic review and meta-analysis[J].BJS Open,2021,5(6):1-8.
[36] WOLCHOK J D,NEYNS B,LINETTE G,et al.Ipilimumab monotherapy in patients with pretreated advanced melanoma:a randomised,double-blind,multicentre,phase 2,dose-ranging study[J].Lancet Oncol,2010,11(2):155-164. |
|
|
|
